Tarsons Products
Tarsons Products Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Guidance rank: #9 of 12 in Healthcare Equipment & Supplies
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
2 of 5 strong
The short version
Tarsons expects sustainable revenue growth driven by expanded capacities and new product launches, particularly from FY’28 onwards. Tarsons expects strong revenue growth driven by ramped-up utilization of expanded capacities and commercialization of new products, especially from FY’28 onwards.
From Tarsons Products's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Tarsons expects sustainable revenue growth driven by expanded capacities and new product launches, particularly from FY’28 onwards.
- Domestic market growth targeted at 15%+ year-on-year, with strong Q1 FY’27 performance exceeding 15% growth.
- New Panchla and Amta facilities expected to contribute 20-25% of standalone revenues by FY’28.
- Cell culture and other new product lines projected to generate approximately INR 65-70 crores in revenue in FY’28.
- Exports showing a healthy recovery with 29% Y-o-Y growth in Q1 FY’27 and expected to be a key growth driver, especially through white-labeling.
- Long-term growth anticipated from greater international presence and integration with Nerbe’s business, including improved product portfolio and geographical expansion.
2 more points from Tarsons Products's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Tarsons Products said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Currently in final phase of large-scale capacity expansion program with significant CAPEX already commissioned and operational.
- Remaining facility commissioning progressing as planned; trial runs underway; full commissioning expected during Q2 FY’27 with revenue contribution starting second half FY’27.
- No major new CAPEX plans for this year besides maintenance; annual maintenance CAPEX expected around INR 20-25 crores.
- Anticipate ramp-up revenues from new Panchla and Amta facilities contributing 20-25% to standalone revenues by FY’28.
- Entire 4-year CAPEX plan expected to enable incremental revenue around INR 400 crores on fixed asset turnover basis, with peak sales potential around INR 750-800 crores.
2 more points from Tarsons Products's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Equipment & Supplies
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Tarsons Products said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Export business inquiries are very promising and strong as long as the environment remains conducive to business.
- Logistics, transportation, and input costs are currently major hurdles, more than tariffs.
- The company experienced a significant benefit from shipments in the latest quarter, affecting revenue recognition, but shipment schedules remain beyond their control due to global logistic challenges.
2 more points from Tarsons Products's call on order book
Create a free account to keep reading this call
Tarsons Products — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹121 Cr, net profit ₹4 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Tarsons Products's management said in earlier quarters
Others in Healthcare Equipment & Supplies this season
- Nureca Ltd (Q1 FY27)
Revenue from Operations for Q1 FY'27: ₹40.3 Cr . Key investor presentation takeaways from Nureca's Q1 FY27 investor presentation — and how it ranks against sect
- Avience Biomedi. (Q1 FY27)
New manufacturing facility has capacity to support peak revenue of around ₹250–265 crore, subject to product mix and approvals. Key concall takeaways from…
- Fischer Medical (Q1 FY27)
The provided pages of the investor presentation do not contain any specific revenue, sales, or volume figures for the quarter, nor details on year-on-year…
- Molbio Diagnosti (Q1 FY27)
Capacity utilization currently at ~58% for test kits and ~42% for devices; automation capex will double revenue capacity with minimal new investment. Key…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Equipment & Supplies
on management's own guidance
- Strong growth2
- Strong growth1
- Molbio DiagnostiGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Tarsons Products and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Tarsons Products Q1 FY27 results?
Tarsons expects sustainable revenue growth driven by expanded capacities and new product launches, particularly from FY’28 onwards. Tarsons expects strong revenue growth driven by ramped-up utilization of expanded capacities and commercialization of new products, especially from FY’28 onwards.
What is Tarsons Products share price analysis?
Tarsons Products currently shows a below-average growth signal. The stock trades at a P/E of 155.0 with a market cap of ₹1,835 Cr. Investors should review the full earnings analysis for detailed insights.
Is Tarsons Products planning capital expenditure?
Currently in final phase of large-scale capacity expansion program with significant CAPEX already commissioned and operational.
Keep Tarsons Products on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.